{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"The MTD is the dose at which a maximum of 1 of 6 patients has a DLT. A DLT is Grade 3 toxicities possibly or probably or definitely related to the Anti-B cell maturation antigen (BCMA) - chimeric antigen receptor (CAR)-expressing T-Cells lasting more than 9 days. Grade 4 toxicities possibly or probably or definitely related to the anti-BCMA CAR T cells. Grade 3 is severe, and Grade 4 is life-threatening.","groups":[{"description":"All participants in Arm 1 Dose Escalation Group who received CAR+T cells, Cyclophosphamide and Fludarabine.","id":"OG000","title":"All Arm 1 Dose Escalation Dose Participants"}],"paramType":"NUMBER","populationDescription":"9/35 participants were enrolled but not treated.","reportingStatus":"POSTED","timeFrame":"First 28 days of treatment","title":"Maximum Tolerated Dose (MTD) of Anti-B Cell Maturation Antigen (BCMA) - Chimeric Antigen Receptor (CAR)-T Cells","type":"PRIMARY","unitOfMeasure":"million CAR + T cells"}